Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC Reviews - August 2013

MTRAC issued a new Commissioning Support review in August 2013. The review covers mirabegron.

The Mirabegron (Betmiga®) summary advises that this drug is suitable for prescribing in primary care. The committee considered the drug to have a lower place in therapy and relatively weak evidence due to limited comparative data with anti-muscarinics and limited long-term efficacy data. The committee also noted that NICE has recommended this treatment as an option for treating overactive bladder (OAB) only for people in whom anti-muscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects.

Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.

Share 'MTRAC Reviews - August 2013' on Email Share 'MTRAC Reviews - August 2013' on Delicious Share 'MTRAC Reviews - August 2013' on Digg Share 'MTRAC Reviews - August 2013' on Facebook Share 'MTRAC Reviews - August 2013' on Google+ Share 'MTRAC Reviews - August 2013' on reddit Share 'MTRAC Reviews - August 2013' on StumbleUpon Share 'MTRAC Reviews - August 2013' on Twitter

atomic-wealth

No Comments to “MTRAC Reviews - August 2013”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,316 spam comments.

atomic-wealth
fond-illness
summer